NASDAQ:IXHL - Nasdaq - US45333F1093 - Common Stock - Currency: USD
Taking everything into account, IXHL scores 2 out of 10 in our fundamental rating. IXHL was compared to 198 industry peers in the Pharmaceuticals industry. IXHL has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, IXHL is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -214.35% | ||
ROE | -2466.94% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.9 | ||
Debt/FCF | N/A | ||
Altman-Z | -22.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.8 | ||
Quick Ratio | 1.8 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.202
-0.02 (-10.62%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 56.79 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 5.77 | ||
P/tB | 5.77 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -214.35% | ||
ROE | -2466.94% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.9 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | 5.1% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.8 | ||
Quick Ratio | 1.8 | ||
Altman-Z | -22.98 |